Genentech’s Fenebrutinib Maintains Near-Complete Suppression of Disease Activity and Disability Progression for up to Two Years in People With Relapsing Multiple Sclerosis
» Report
Einige Inhalte dieser Seite sind nur für Abonnenten sichtbar.
Anmelden oder
Jetzt abonnieren!
Archiv: Unternehmen
CI Com: Annonce événementielle au sens de l'art. 53 RC
» Report
Private Equity Holding AG: Annual General Meeting on June 24, 2025 in Zurich
» Report
Private Equity Holding AG: Generalversammlung vom 24. Juni 2025 in Zürich
» Report
Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis
» Report
GURIT ANNOUNCES CHANGES IN THE EXECUTIVE BOARD
» Report
Meyer Burger shuts down solar module production and lays off 282 employees in the U.S.
» Report
Meyer Burger stoppt Solarmodulproduktion und entlässt 282 Mitarbeitende in den USA
» Report
Alcon - Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
» Report
Logitech - SD (Specialized Disclosure Report) SEC Filing
» Report
SHL announces 2025 Annual General Meeting Results
» Report
Kuehne+Nagel Group: Kuehne+Nagel appoints new Global Head of Sales
» Report
Glencore: Results of 2025 AGM
» Report
Cantor Fitzgerald expands asset management capabilities with acquisition of UBS’s O’Connor alternatives investment platform
» Report
Nestlé expands its air fryer range in the Americas, offering delicious meal moments
» Report
Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2025
» Report
Galderma buys back shares worth CHF 233 million in the context of accelerated bookbuild offering
» Report
Ascom launches share buyback program
» Report
Ascom lanciert Aktienrückkaufprogramm
» Report
Landis+Gyr veröffentlicht Geschäftsbericht 2024 und Einladung zur Generalversammlung 2025
» Report
